Neumirna Therapeutics, a Copenhagen, Denmark-based RNA-focused biotech firm, raised €20M in Collection A funding.
The spherical was led by Angelini Ventures and Invivo Companions with participation from Innovestor’s Life Science Fund and different present buyers.
The corporate intends to make use of the funds to assist scientific improvement of its lead asset NMT.001, a possible disease-modifying Antisense Oligonucleotide (ASO) remedy for drug-resistant epilepsy, in addition to develop its R&D capabilities and scale its pioneering drug discovery platform.
Based in 2020 by Dr. Henrik Klitgaard, Prof. Sakari Kauppinen and Lars Hellerung Christiansen, and led by CEO Professor Janine Erler, Neumirna is a biotechnology firm centered on growing RNA-based therapies offering a drug improvement platform that permits the event of RNA therapies focusing on beforehand intractable situations, reminiscent of drug-resistant epilepsy (DRE) and Parkinson’s illness.
FinSMEs
08/01/2025
